Evidence map›Paper›PMID 37958554›Full record

ArticleInternational journal of molecular sciences2023

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach.

Angeliki Katsenou, Roisin O'Farrell, Paul Dowling, Caroline A Heckman, Peter O'Gorman, Despina Bazou

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Angeliki KatsenouDepartment of Electronics and Electrical Engineering, Trinity College Dublin, D02 PN40 Dublin, Ireland.ORCID 0000-0003-0081-4488
Roisin O'FarrellDepartment of Electronics and Electrical Engineering, Trinity College Dublin, D02 PN40 Dublin, Ireland.
Paul DowlingDepartment of Biology, Maynooth University, W23 F2K8 Kildare, Ireland.ORCID 0000-0002-9290-9267
Caroline A HeckmanInstitute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-4324-8706
Peter O'GormanDepartment of Haematology, Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland.
Despina BazouSchool of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland.ORCID 0000-0002-0934-1106

Funding

Health Research Board HRCI-HRB-2020-022
6 · The paper itself

Abstract

This paper describes a machine learning (ML) decision support system to provide a list of chemotherapeutics that individual multiple myeloma (MM) patients are sensitive/resistant to, based on their proteomic profile. The methodology used in this study involved understanding the parameter space and selecting the dominant features (proteomics data), identifying patterns of proteomic profiles and their association to the recommended treatments, and defining the decision support system of personalized treatment as a classification problem. During the data analysis, we compared several ML algorithms, such as linear regression, Random Forest, and support vector machines, to classify patients as sensitive/resistant to therapeutics. A further analysis examined data-balancing techniques that emerged due to the small cohort size. The results suggest that utilizing proteomics data is a promising approach for identifying effective treatment options for patients with MM (reaching on average an accuracy of 81%). Although this pilot study was limited by the small patient cohort (39 patients), which restricted the training and validation of the explored ML solutions to identify complex associations between proteins, it holds great promise for developing personalized anti-MM treatments using ML approaches.

Indexed as

Multiple MyelomaProteomicsAlgorithmsHumansMachine LearningPilot ProjectsSupport Vector Machinedrug sensitivity scoremachine learningmultiple myelomaproteomics

Identifiers

PMID37958554
PMCPMC10650823

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.